Fiduciary Alliance LLC Purchases Shares of 13,275 Anavex Life Sciences Corp. (NASDAQ:AVXL)

Fiduciary Alliance LLC bought a new position in shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 13,275 shares of the biotechnology company’s stock, valued at approximately $67,000.

Several other institutional investors also recently bought and sold shares of the stock. Orion Capital Management LLC purchased a new position in Anavex Life Sciences during the third quarter worth approximately $59,000. Dark Forest Capital Management LP purchased a new stake in shares of Anavex Life Sciences in the 3rd quarter valued at approximately $76,000. China Universal Asset Management Co. Ltd. lifted its holdings in shares of Anavex Life Sciences by 351.6% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 9,498 shares of the biotechnology company’s stock worth $88,000 after acquiring an additional 7,395 shares during the last quarter. Belpointe Asset Management LLC purchased a new position in shares of Anavex Life Sciences during the 4th quarter worth approximately $93,000. Finally, Tower Research Capital LLC TRC increased its holdings in Anavex Life Sciences by 32.3% in the 4th quarter. Tower Research Capital LLC TRC now owns 10,637 shares of the biotechnology company’s stock valued at $99,000 after purchasing an additional 2,594 shares during the last quarter. 31.55% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $40.00 price target on shares of Anavex Life Sciences in a research note on Tuesday, June 11th.

Anavex Life Sciences Price Performance

NASDAQ AVXL opened at $4.22 on Monday. The company has a market cap of $357.19 million, a P/E ratio of -8.44 and a beta of 0.67. The stock has a 50-day moving average of $3.96 and a two-hundred day moving average of $5.23. Anavex Life Sciences Corp. has a 1-year low of $3.25 and a 1-year high of $10.45.

Anavex Life Sciences (NASDAQ:AVXL) last announced its earnings results on Thursday, May 9th. The biotechnology company reported ($0.13) earnings per share for the quarter, hitting the consensus estimate of ($0.13). During the same quarter in the previous year, the company earned ($0.17) EPS. On average, analysts anticipate that Anavex Life Sciences Corp. will post -0.55 EPS for the current fiscal year.

About Anavex Life Sciences

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.